```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN
 NEWS  4  JUN 26  NUTRACEUT and PHARMAML no longer updated
 NEWS  5  JUN 29  IMSCOPROFILE now reloaded monthly
 NEWS  6  JUN 29  EPFULL adds Simultaneous Left and Right Truncation
                  (SLART) to AB, MCLM, and TI fields
 NEWS  7  JUL 09  PATDPAFULL adds Simultaneous Left and Right
                  Truncation (SLART) to AB, CLM, MCLM, and TI fields
 NEWS  8  JUL 14  USGENE enhances coverage of patent sequence location
                  (PSL) data
 NEWS  9  JUL 27  CA/CAplus enhanced with new citing references
 NEWS 10  JUL 16  GBFULL adds patent backfile data to 1855
 NEWS 11  JUL 21  USGENE adds bibliographic and sequence information
 NEWS 12  JUL 28  EPFULL adds first-page images and applicant-cited
                  references
 NEWS 13  JUL 28  INPADOCDB and INPAFAMDB add Russian legal status data

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:42:31 ON 07 AUG 2009

=> b reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22
```

```
FILE 'REGISTRY' ENTERED AT 08:42:53 ON 07 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 AUG 2009  HIGHEST RN 1173150-47-4
DICTIONARY FILE UPDATES:   5 AUG 2009  HIGHEST RN 1173150-47-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e fenofibrate/cn
E1            1     FENOFEN M/CN
E2            1     FENOFERIN/CN
E3            1 --> FENOFIBRATE/CN
E4            1     FENOFIBRATE-FOLIC ACID-VITAMIN B6 MIXT./CN
E5            1     FENOFIBRIC ACID/CN
E6            1     FENOFIBRIC ACID TRIS SALT/CN
E7            1     FENOFIX 120/CN
E8            1     FENOFLURAZOLE/CN
E9            1     FENOFOR B/CN
E10           1     FENOFOR BB/CN
E11           1     FENOFOR BFB/CN
E12           1     FENOFOR BK/CN

=> s e3
L1            1 FENOFIBRATE/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   49562-28-9  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
     ester  (CA INDEX NAME)
OTHER NAMES:
CN   Ankebin
CN   Antara
CN   Clorofibrate
CN   Elasterin
CN   Fenobrate
CN   Fenofibrate
CN   Fenogal
CN   Fenotard
```

CN Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
CN LF 178
CN Lipanthyl
CN Lipantil
CN Lipicard
CN Lipidil
CN Lipidil Supra
CN Lipirex
CN Lipoclar
CN Lipofene
CN Liposit
CN Lipsin
CN MeltDose
CN Nolipax
CN NSC 281319
CN Procetofen
CN Procetofene
CN Procetoken
CN Protolipan
CN Secalip
CN TriCor
MF C20 H21 Cl O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PIRA, PROMT, PS, RTECS*, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2028 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2038 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e voglibose/cn
E1 1 VOGGITE/CN
E2 1 VOGGITE (NA2ZR(CO3)(OH)(PO4).2H2O)/CN
E3 1 --> VOGLIBOSE/CN
E4 1 VOGLISTAT/CN
E5 1 VOGLITE/CN
E6 1 VOGTITE/CN
E7 1 VOIDOX/CN

```
E8              1     VOILOKARB/CN
E9              1     VOK/CN
E10             1     VOK 71/CN
E11             1     VOK-60/CN
E12             1     VOK-63/CN

=> s e3
L2              1 VOGLIBOSE/CN

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   83480-29-9  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-
     C-(hydroxymethyl)-  (CA INDEX NAME)
OTHER NAMES:
CN   A 71100
CN   AO 128
CN   Basen
CN   Glustat
CN   N-(1,3-Dihydroxy-2-propyl)valiolamine
CN   Voglibose
CN   Voglistat
FS   STEREOSEARCH
DR   112653-29-9
MF   C10 H21 N O7
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT,
       IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (+).
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             320 REFERENCES IN FILE CA (1907 TO DATE)
               6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             322 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> b caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    15.28      15.50

FILE 'CAPLUS' ENTERED AT 08:43:25 ON 07 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 7 Aug 2009  VOL 151 ISS 7
FILE LAST UPDATED: 6 Aug 2009  (20090806/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 22.

=> s l1 and l2 and py<=2005
          2039 L1
           322 L2
      26321211 PY<=2005
L3           8 L1 AND L2 AND PY<=2005

=> d l3 1-8 ibib abs hitstr

L3   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:1075524  CAPLUS
DOCUMENT NUMBER:          143:367288
TITLE:                    Preparation of 1,6-naphthyridine and 1,8-naphthyridine
                          derivatives and their use to treat diabetes and
                          related disorders
INVENTOR(S):              Heurich, Rainer
```

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005091857	A2	20051006	WO 2005-US5367	20050224 <--
WO 2005091857	A3	20061005		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-552971P P 20040312
OTHER SOURCE(S): CASREACT 143:367288; MARPAT 143:367288
GI



I II

AB The title compds. I and II [R1 = alkyl, alkenyl, alkynyl, aryl, etc.; R2 = NR15R16, S(O)0-2R17, OR17 (wherein R15 = H, alkyl, cycloalkyl, etc.; R16 = alkyl, alkenyl, aryl, etc.; R17 = alkyl, alkenyl, aryl, etc.); R3 = aryl, heteroaryl, cycloalkyl, etc.; R4 = O, S, OR21 (R21 = H, alkyl, cycloalkyl, etc.); R5-R8 = cycloalkyl, aryl, heteroaryl, etc.], useful for the treatment of diabetes and related disorders (no specific biol. data given), were prepared Thus, reacting 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one with morpholine in dioxane afforded 92% 5-methyl-7-(morpholin-4-yl)-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one. The pharmaceutical compns. containing the compds. I alone or in combination with other therapeutic agents are disclosed.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of 1,6-naphthyridine and 1,8-naphthyridine derivs. for treating diabetes and related disorders)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823553 CAPLUS
DOCUMENT NUMBER: 143:199940
TITLE: Combination drug containing antihyperlipidemics and α-glucosidase inhibitors
INVENTOR(S): Kanazawa, Hashime; Ishitani, Kouki; Sudo, Katsuichi; Tanimori, Naoto
PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074909	A1	20050818	WO 2005-JP1801	20050208 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2555316 A1 20050818 CA 2005-2555316 20050208 <--
EP 1714648 A1 20061025 EP 2005-709853 20050208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU
US 20070197602 A1 20070823 US 2006-588725 20060808
PRIORITY APPLN. INFO.: JP 2004-32329 A 20040209
WO 2005-JP1801 W 20050208

AB Disclosed is a drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compds. (fenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase inhibitors (statin compds. such as pravastatin, atorvastatin, salts thereof, etc.) with an α-glucosidase inhibitor (voglibose, acarbose, etc.). The content of the α-glucosidase inhibitor may be from 0.001 to 50 parts by weight per 100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to provide a drug having excellent effects of preventing and/or treating metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc. with little side effect. For example, the effect of combination of fenofibrate and voglibose was examined in streptozotocin-induced diabetic rats. Also, a tablet containing fenofibrate 100, voglibose 0.2, lactose 69.2, fine crystalline cellulose 29.6, magnesium stearate 1 mg was formulated.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination drug containing antihyperlipidemics and α-glucosidase inhibitors)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:729537 CAPLUS
DOCUMENT NUMBER: 143:211920
TITLE: Preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics.
INVENTOR(S): Ogawa, Nobuya; Okuma, Chihiro; Furukawa, Noboru
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan; Amgen Sf, LLC
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072740	A2	20050811	WO 2005-JP1643	20050128 <--
WO 2005072740	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005209115	A1	20050811	AU 2005-209115	20050128 <--
CA 2554455	A1	20050811	CA 2005-2554455	20050128 <--
EP 1718309	A2	20061108	EP 2005-704403	20050128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1913899	A	20070214	CN 2005-80003524	20050128
JP 2007519605	T	20070719	JP 2006-524132	20050128
US 20070027093	A1	20070201	US 2006-495095	20060728
KR 2006114376	A	20061106	KR 2006-717527	20060830
IN 2006CN03150	A	20070608	IN 2006-CN3150	20060830
PRIORITY APPLN. INFO.:			JP 2004-24812 A	20040130

US 2004-598037P P 20040802
WO 2005-JP1643 W 20050128
OTHER SOURCE(S): CASREACT 143:211920; MARPAT 143:211920
GI



I

AB Claimed are anorectics comprising as active ingredients compds. having DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrugs or a pharmaceutically acceptable salts thereof. Thus, title compound (I) (preparation
given) at 10 mg/kg orally in rats gave a 30% reduction in food consumption after 8 h.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:120729 CAPLUS
DOCUMENT NUMBER: 142:219276
TITLE: Preparation of 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the RUP25 nicotinic acid receptor for the treatment of dyslipidemia and related diseases
INVENTOR(S): Semple, Graeme; Gharbaoui, Tawfik; Shin, Young-Jun; Decaire, Marc; Averbuj, Claudia; Skinner, Philip J.
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011677	A1	20050210	WO 2004-US18389	20040610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260636	A1	20050210	AU 2004-260636	20040610 <--
CA 2528834	A1	20050210	CA 2004-2528834	20040610 <--
EP 1633351	A1	20060315	EP 2004-776418	20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070032537	A1	20070208	US 2006-560332	20060908
PRIORITY APPLN. INFO.:			US 2003-478664P	P 20030613
			WO 2004-US18389	W 20040610

OTHER SOURCE(S): MARPAT 142:219276
GI



I

AB Title compds. [I; W, Y = (substituted) alkylene, alkenylene, alkynylene; X = NR3CO, NR3SO2, NR3, CO, CH(OH), C(NH), O, S, SO, SO2, etc.; R3, R4 = H, (substituted) alkyl, Ph, heteroaryl; Z = H, halo, (substituted) Ph, heteroaryl; R1 = H, OH, halo, alkyl, haloalkyl; R2 = H, alkyl; m, n = 0, 1; with provisos], were prepared Thus, 5-methylthiomethyl-2H-pyrazole-3-carboxylic acid (preparation outlined) showed hRUP25 agonist activity with EC50 = 4.3 μM.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of pyrazolecarboxylates as agonists for the RUP25 nicotinic acid receptor for the treatment of dyslipidemia and related diseases)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:14212 CAPLUS
DOCUMENT NUMBER: 142:107414
TITLE: Compositions comprising balaglitazone and further antidiabetic compounds
INVENTOR(S): Wassermann, Karsten; Wulff, Erik Max
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000299	A1	20050106	WO 2004-DK448	20040624 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004250994	A1	20050106	AU 2004-250994	20040624 <--
CA 2530228	A1	20050106	CA 2004-2530228	20040624 <--
EP 1638554	A1	20060329	EP 2004-738945	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012009	A	20060815	BR 2004-12009	20040624
CN 1826112	A	20060830	CN 2004-80020764	20040624
JP 2007506649	T	20070322	JP 2006-515731	20040624
NZ 544307	A	20081224	NZ 2004-544307	20040624
US 20070010423	A1	20070111	US 2005-561639	20051220
KR 2006105431	A	20061011	KR 2005-724956	20051226
ZA 2006000735	A	20070530	ZA 2006-735	20060125
PRIORITY APPLN. INFO.:			DK 2003-973 A	20030627
			US 2003-483196P P	20030627
			WO 2004-DK448 W	20040624

AB Methods for the treatment of type 2 diabetes and related conditions comprising the administration of balaglitazone in combination with one or more other antidiabetic compound is provided together with combinations useful in said treatment.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising balaglitazone and further antidiabetic compds.)

RN 49562-28-9 CAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1124581 CAPLUS
DOCUMENT NUMBER: 142:69181
TITLE: Combination therapy for the treatment of hypertension
INVENTOR(S): Fong, Tung M.; Erondu, Ngozi E.; Macneil, Douglas J.; Mcintyre, James H.; Van Der Ploeg, Leonardus H. T.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110368	A2	20041223	WO 2004-US17090	20040602 <--
WO 2004110368	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1635773 A2 20060322 EP 2004-753832 20040602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

US 20060160834 A1 20060720 US 2005-559111 20051202

PRIORITY APPLN. INFO.: US 2003-476390P P 20030606
WO 2004-US17090 W 20040602

OTHER SOURCE(S): MARPAT 142:69181

AB The present invention relates to compns. comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

IT ***49562-28-9***, Tricor ***83480-29-9***, Voglibose
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

RN 49562-28-9 CAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:878382 CAPLUS
DOCUMENT NUMBER: 141:350161
TITLE: Preparation of azole compounds as PTP1B inhibitors
INVENTOR(S): Ikemoto, Tomoyuki; Tanaka, Masahiro; Yuno, Takeo; Sakamoto, Johei; Nakanishi, Hiroyuki; Nakagawa, Yuichi; Ohta, Takeshi; Sakata, Shohei; Morinaga, Hisayo
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 542 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004089918	A1	20041021	WO 2004-JP5119	20040409	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004228565	A1	20041021	AU 2004-228565	20040409	<--
CA 2521830	A1	20041021	CA 2004-2521830	20040409	<--
EP 1553091	A1	20050713	EP 2004-726765	20040409	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004009136	A	20060425	BR 2004-9136	20040409	
CN 1780823	A	20060531	CN 2004-80009487	20040409	
JP 3819415	B2	20060906	JP 2005-505323	20040409	
ZA 2005008481	A	20070425	ZA 2005-8481	20040409	
JP 2005272476	A	20051006	JP 2005-133755	20050428	<--
US 20060122181	A1	20060608	US 2005-176846	20050707	
NO 2005005246	A	20051221	NO 2005-5246	20051108	<--
IN 2005CN02927	A	20070608	IN 2005-CN2927	20051109	
PRIORITY APPLN. INFO.:			JP 2003-105267	A 20030409	
			JP 2003-157590	A 20030603	
			JP 2005-505323	A3 20040409	
			WO 2004-JP5119	W 20040409	

OTHER SOURCE(S): MARPAT 141:350161
GI





AB Title compds. I [V = N, CH; W = S, O; m = 0-2; R1, R2 = H, alkyl; X = NR4, etc.; R4 = H, alkyl; n = 0-4; p = 0, 1; L = CR20R21, etc.; R20 = H, alkyl, etc.; R21 = H, alkyl, etc.; R = CO2R19, etc.; R19 = H, alkyl; B = aryl, heteroaryl; R3 = H, halo, etc.; Y = O, etc.; s = 0, 1; A = (un)substituted alkylene with cycloalkyl; Z = cycloalkyl, etc.] were prepared For example, O-alkylation of 5-hydroxynicotinic acid Me ester with compound II [Q = Cl], e.g., prepared from 4-bromoacetylbenzoic acid in 5 steps, followed by saponification
afforded compound II [3-carboxypyridin-5-yloxy] in 44.1% overall yield. In PTP1B (protein tyrosine phosphatase 1B) inhibition assays, the IC50 value of compound II [Q = 3-carboxypyridin-5-yloxy] was 0.28 μM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of azole compds. as PTP1B inhibitors for treatment of obesity and diabetes)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:333698 CAPLUS
DOCUMENT NUMBER: 140:357333
TITLE: Preparation of aroylhydroxypyrazoles for treatment of metabolic disorders
INVENTOR(S): Semple, Graeme; Shin, Young Jun
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033431	A2	20040422	WO 2003-US31509	20031002 <--
WO 2004033431	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282679	A1	20040504	AU 2003-282679	20031002 <--

PRIORITY APPLN. INFO.:
US 2002-416193P P 20021004
US 2002-417120P P 20021007
WO 2003-US31509 W 20031002

OTHER SOURCE(S): MARPAT 140:357333
GI



I

AB Title compds. [I; R1 = alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, benzyl, optionally substituted with ≥1 halo, OH, cyano, NO2, haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalklcylsulfonyl, alkylureyl, arylureyl; R2 = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, PhCH2, Ph, heteroaryl, optionally substituted with ≥1 halo, OH, cyano, nitro, haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfmyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalkylsulfonyl, alkylureyl or arylureyl groups; Ar = (substituted) pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl], were prepared for the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like (no data). Thus, nicotinyl chloride, 2-methyl-5-propyl-2,4-dihydropyrazol-3-one, and Ca(OH)2 were heated at 90° in dioxane for 2 h. to give (5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)pyridin-3-ylmethanone. I may be used in combination with other active agents such α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme inhibitors, and insulin secretion enhancers.

IT ***49562-28-9***, Fenofibrate ***83480-29-9***, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of aroylhydroxypyrazoles for treatment of metabolic disorders)

RN 49562-28-9 CAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 08:42:31 ON 07 AUG 2009)

FILE 'REGISTRY' ENTERED AT 08:42:53 ON 07 AUG 2009
E FENOFIBRATE/CN
L1 1 S E3
E VOGLIBOSE/CN
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 08:43:25 ON 07 AUG 2009
L3 8 S L1 AND L2 AND PY<=2005

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.86	64.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.56	-6.56

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:45:16 ON 07 AUG 2009